Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

36.8%

7 terminated/withdrawn out of 19 trials

Success Rate

63.2%

-23.3% vs industry average

Late-Stage Pipeline

16%

3 trials in Phase 3/4

Results Transparency

83%

10 of 12 completed trials have results

Key Signals

10 with results7 terminated

Enrollment Performance

Analytics

Phase 2

13(72.2%)

Phase 3

3(16.7%)

Phase 1

2(11.1%)

18Total

Phase 2(13)

Phase 3(3)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT00955409Phase 2Completed

Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Role: collaborator

NCT00916617Phase 2Terminated

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Role: collaborator

NCT01369225Phase 1Completed

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Role: collaborator

NCT01193608Phase 1Completed

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Role: collaborator

NCT00960531Phase 2Terminated

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Role: collaborator

NCT01227564Phase 2Completed

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

Role: collaborator

NCT00498602Phase 2Completed

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Role: collaborator

NCT00959192Phase 2Completed

Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Role: collaborator

NCT00752232Phase 2Completed

Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

Role: collaborator

NCT01658722Terminated

Retrieval of Patient Information After Discontinuation

Role: lead

NCT01284387Phase 2Completed

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease

Role: lead

NCT01238991Phase 2Terminated

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Role: collaborator

NCT01254773Phase 2Completed

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease

Role: lead

NCT00937352Phase 3Terminated

A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

Role: lead

NCT00574132Phase 3Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Role: lead

NCT00606476Phase 2Terminated

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

Role: lead

NCT00575055Phase 3Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

Role: lead

NCT00112073Phase 2Completed

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

Role: lead

NCT00021723Phase 2Terminated

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

Role: lead

All 19 trials loaded